GEP20115332B - Herbal composition for inflammatory disorders - Google Patents

Herbal composition for inflammatory disorders

Info

Publication number
GEP20115332B
GEP20115332B GEAP200610647A GEAP2006010647A GEP20115332B GE P20115332 B GEP20115332 B GE P20115332B GE AP200610647 A GEAP200610647 A GE AP200610647A GE AP2006010647 A GEAP2006010647 A GE AP2006010647A GE P20115332 B GEP20115332 B GE P20115332B
Authority
GE
Georgia
Prior art keywords
herbal composition
inflammatory disorders
composition
flowering
concerns
Prior art date
Application number
GEAP200610647A
Other languages
English (en)
Inventor
Sapna Hasit Parikh
Asha Kulkarni-Almeida
Ashok Kumar Gangopadhyay
Swati Bal-Tembe
Dhananjay Sapre
Ashish Suthar
Vijay Chauhan
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of GEP20115332B publication Critical patent/GEP20115332B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
GEAP200610647A 2005-09-30 2006-09-28 Herbal composition for inflammatory disorders GEP20115332B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1226MU2005 2005-09-30
US73644305P 2005-11-14 2005-11-14

Publications (1)

Publication Number Publication Date
GEP20115332B true GEP20115332B (en) 2011-11-25

Family

ID=37900158

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200610647A GEP20115332B (en) 2005-09-30 2006-09-28 Herbal composition for inflammatory disorders

Country Status (10)

Country Link
US (2) US7635494B2 (cg-RX-API-DMAC7.html)
EP (1) EP1931366B1 (cg-RX-API-DMAC7.html)
JP (1) JP5331962B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006296197B2 (cg-RX-API-DMAC7.html)
CA (1) CA2624049C (cg-RX-API-DMAC7.html)
EA (1) EA014070B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20115332B (cg-RX-API-DMAC7.html)
MA (1) MA29890B1 (cg-RX-API-DMAC7.html)
PL (1) PL1931366T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007036900A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981131B2 (en) * 2007-07-27 2015-03-17 Piramal Enterprises Limited Tricyclic compounds for the treatment of inflammatory disorders
WO2009084032A2 (en) * 2007-12-03 2009-07-09 Vedic Elements Private Limited Stable hydrophobic topical herbal formulation
WO2012014216A1 (en) * 2010-07-28 2012-02-02 Laila Nutraceuticals 7-hydroxyfrullanolide and its analogs for prevention, control and treatment of metabolic disorders
US10105347B2 (en) 2009-02-02 2018-10-23 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
CN102292093B (zh) * 2009-02-02 2015-01-28 莱拉营养食品有限公司 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
WO2011033524A2 (en) * 2009-08-04 2011-03-24 Laila Nutraceuticals Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases
WO2011083397A1 (en) * 2010-01-05 2011-07-14 Himalaya Global Holdings Limited Herbal composition for skin disorders
PH12013500451A1 (en) * 2010-09-11 2013-05-20 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
US8263579B2 (en) * 2011-01-24 2012-09-11 Piramal Healthcare Limited Anti-inflammatory compounds
TW201427677A (zh) * 2012-10-23 2014-07-16 Piramal Entpr Ltd 用於預防及治療腫瘤壞死因子-α媒介疾病中藥組合物
EP3313384A4 (en) 2015-06-23 2019-04-03 Nobilis Therapeutics, Inc. THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS
WO2017203540A1 (en) * 2016-05-21 2017-11-30 Laila Impex Dietary supplements and compositions for enhancing physical performance and energy levels

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646687A (en) * 1994-12-29 1997-07-08 Lucent Technologies Inc. Temporally-pipelined predictive encoder/decoder circuit and method
US6204523B1 (en) * 1998-11-06 2001-03-20 Lumileds Lighting, U.S., Llc High stability optical encapsulation and packaging for light-emitting diodes in the green, blue, and near UV range
US6686676B2 (en) * 2001-04-30 2004-02-03 General Electric Company UV reflectors and UV-based light sources having reduced UV radiation leakage incorporating the same
US6989412B2 (en) * 2001-06-06 2006-01-24 Henkel Corporation Epoxy molding compounds containing phosphor and process for preparing such compositions
US6841647B2 (en) * 2001-11-06 2005-01-11 National Starch And Chemical Investment Holding Corporation Fluid resistant silicone encapsulant
US7160972B2 (en) * 2003-02-19 2007-01-09 Nusil Technology Llc Optically clear high temperature resistant silicone polymers of high refractive index
US7261441B2 (en) * 2004-02-27 2007-08-28 Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. LED device and method for directing LED light
WO2006016228A2 (en) * 2004-08-02 2006-02-16 Prashanth Kumar V Cytotoxic peptide alkaloid and pharmaceutical compositions for the treatment of neoplastic diseases
US7229934B2 (en) * 2004-10-18 2007-06-12 International Business Machines Corporation Porous organosilicates with improved mechanical properties

Also Published As

Publication number Publication date
CA2624049A1 (en) 2007-04-05
WO2007036900A2 (en) 2007-04-05
HK1112418A1 (en) 2008-09-05
CA2624049C (en) 2016-01-12
AU2006296197A2 (en) 2008-06-05
MA29890B1 (fr) 2008-10-03
AU2006296197A1 (en) 2007-04-05
US7635494B2 (en) 2009-12-22
US20090269427A1 (en) 2009-10-29
JP5331962B2 (ja) 2013-10-30
JP2009510051A (ja) 2009-03-12
EA200800850A1 (ru) 2008-10-30
US20080254157A1 (en) 2008-10-16
AU2006296197B2 (en) 2012-08-09
PL1931366T3 (pl) 2013-11-29
US8206756B2 (en) 2012-06-26
WO2007036900A3 (en) 2007-08-02
EP1931366B1 (en) 2013-05-29
EA014070B1 (ru) 2010-08-30
EP1931366A2 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2007109804A3 (en) Extracts and methods comprising cinnamon species
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2007109801A3 (en) Extracts and methods comprising ganoderma species
WO2007109802A3 (en) Extracts and methods comprising green tea species
TW200510416A (en) P38 inhibitors and methods of use thereof
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
PH12013500356A1 (en) Engineered anti-tslp antibody
TW200628159A (en) IL-12 modulatory compounds
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
WO2009032888A3 (en) Method for providing energy, relieving stress and mood enhancing benefits comprising administering a composition comprising cholecalciferol and a tea extract
WO2009129246A3 (en) Compositions and methods for preparing and using same
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
WO2008061109A3 (en) Indazole derivatives useful as melanin concentrating receptor ligands
MX337933B (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
WO2010013254A3 (en) Withania somnifera plant extract and method of preparation thereof
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
ZA201003221B (en) Tea composition and process for the manufacture thereof
TW200720256A (en) IL-12 modulatory compounds
WO2008140641A3 (en) Pure paliperidone and processes for preparing thereof
WO2008104590A3 (en) Novel dosage form
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.
WO2005073152A3 (de) Verfahren zur herstellung von polyisobutenylphenolen
WO2006078699A3 (en) Oral care compositions derived from the labiatae family
WO2005112965A3 (en) Botanical anti-inflammatory compositions and methods